GlycoMimetics has been granted a patent for compounds, compositions, and methods for treating diseases by inhibiting E-selectin binding. The patent includes E-selectin antagonists and pharmaceutical compositions. GlobalData’s report on GlycoMimetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights GlycoMimetics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GlycoMimetics, Cancer treatment biomarkers was a key innovation area identified from patents. GlycoMimetics's grant share as of February 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment and prevention of diseases by inhibiting e-selectin binding

Source: United States Patent and Trademark Office (USPTO). Credit: GlycoMimetics Inc

The granted patent (Publication Number: US11878026B2) discloses a series of claims related to compounds known as glycomimetic E-selectin antagonists. These compounds are detailed in various formulas and are intended for use in compositions with other pharmaceutically acceptable ingredients. The patent also covers methods for treating various conditions by administering these compounds, including inflammatory diseases, cancer, and metastasis of cancer cells. Additionally, the patent describes methods for inhibiting the infiltration of cancer cells into specific organs like the liver, lymph nodes, lung, bone, and bone marrow.

Furthermore, the patent outlines a method for enhancing hematopoietic stem cell survival by administering the disclosed compounds. It also includes combinations of the compounds with chemotherapy or radiotherapy for treating cancer. The claims within the patent cover a wide range of applications for these glycomimetic E-selectin antagonists, emphasizing their potential in addressing various diseases, disorders, and conditions where inhibition of E-selectin mediated functions is beneficial. The patent provides a comprehensive framework for utilizing these compounds in therapeutic interventions, particularly in the context of cancer treatment and management.

To know more about GlobalData’s detailed insights on GlycoMimetics, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies